Results 101 to 110 of about 45,236 (268)
Cancer pain: current practice and emerging targets
British Journal of Pharmacology, EarlyView.Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye +5 more
wiley +1 more source
Frequent mild head injury promotes trigeminal sensitivity concomitant with microglial proliferation, astrocytosis, and increased neuropeptide levels in the trigeminal pain system. [PDF]
, 2017 BACKGROUND: Frequent mild head injuries or concussion along with the presence of headache may contribute to the persistence of concussion symptoms. METHODS: In this study, the acute effects of recovery between mild head injuries and the frequency of ...
Assari, Soroush +4 more
core +2 more sources
Amylin analogues as a novel perspective in anti‐obesity therapy
British Journal of Pharmacology, EarlyView.Abstract Public health systems face a major challenge because of the worldwide obesity epidemic. The number of obese individuals has increased dramatically and, even in Switzerland which may be considered a relatively “lean” country, the numbers are alarmingly high and have reached almost 50% of the adult population.
Thomas A. Lutz
wiley +1 more source
The Journal of Headache and Pain, 2019 Background Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor are efficacious for the prevention of migraine headaches.
Raffi Manoukian +5 more
doaj +1 more source
The Journal of Headache and Pain, 2019 Background Monoclonal antibodies (mAbs) towards CGRP or the CGRP receptor show good prophylactic antimigraine efficacy. However, their site of action is still elusive.
Jacob C. A. Edvinsson +6 more
doaj +1 more source
Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2). [PDF]
, 2019 BACKGROUND: Patients with high-frequency episodic migraine (HFEM) have a greater disease burden than those with low-frequency episodic migraine (LFEM).
Day, Katie A. +4 more
core +1 more source
Effectiveness and acceptability of oral migraine preventives: A prospective, observational study
Headache: The Journal of Head and Face Pain, EarlyView.Abstract Objective To explore the adherence, effectiveness, safety, tolerability, and acceptability of frequently used oral migraine preventive drugs in a real‐world setting. Background Oral migraine preventives are previously mainly explored in randomized controlled trials, whereas real‐world data on treatment outcomes remain limited. Methods MigriNor
Hedda S. Riise +13 more
wiley +1 more source
The Calcitonin/Calcitonin Gene-Related Peptide Family in Invertebrate Deuterostomes
Frontiers in Endocrinology, 2018 Calcitonin (CT)/CT gene-related peptide (CGRP) family peptides (CT/CGRP family peptides) including CT, CGRP, adrenomedullin, amylin, and CT receptor-stimulating peptide have been identified from various vertebrates and perform a variety of important ...
Toshio Sekiguchi
doaj +1 more source
Headache: The Journal of Head and Face Pain, EarlyView.Abstract Objective This study aimed to evaluate demographic characteristics, treatment effectiveness, and safety outcomes in patients with migraine undergoing anti‐calcitonin gene‐related peptide (CGRP) treatments regarding the presence of autoimmune diseases. Background CGRP has an important role in migraine pathophysiology through neuronal modulation
María Clara García‐Castillo +37 more
wiley +1 more source
Drug Design, Development and TherapyMengyi Li, Siyong Huang, Jiabao Li, Xiao Hu, Jisheng Chen Key Specialty of Clinical Pharmacy, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People’s Republic of ChinaCorrespondence: Jisheng Chen, Key Specialty of ...
Li M, Huang S, Li J, Hu X, Chen J
doaj